Stay updated on Rebastinib with Paclitaxel in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page.

Latest updates to the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedLocations information has been reorganized into a single Locations section listing all participating states (Alabama, Colorado, Illinois, Kansas, Massachusetts, New York, Ohio, Oklahoma, Pennsylvania, Rhode Island, Tennessee, Texas), replacing the prior per-state location blocks.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.3.2 added and v3.2.0 removed. No content changes to study data are involved.SummaryDifference0.0%

- Check39 days agoChange DetectedThe government funding status notice on the page has been removed.SummaryDifference0.3%

- Check54 days agoChange DetectedNo significant changes to core study information (eligibility criteria, outcomes, or locations); only minor formatting and layout adjustments were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check82 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%

- Check89 days agoChange DetectedUpdate: replacing older terms with Carcinosarcoma and updating version to v3.1.0; older term references (Ovarian cancer, Mixed Tumor, Mesodermal) and v3.0.2 are removed.SummaryDifference0.2%

Stay in the know with updates to Rebastinib with Paclitaxel in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page.